Prestige BioPharma Balance Sheet Health
Financial Health criteria checks 5/6
Prestige BioPharma has a total shareholder equity of ₩515.5B and total debt of ₩103.5B, which brings its debt-to-equity ratio to 20.1%. Its total assets and total liabilities are ₩711.7B and ₩196.2B respectively.
Key information
20.1%
Debt to equity ratio
₩103.53b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩228.81b |
| Equity | ₩515.50b |
| Total liabilities | ₩196.22b |
| Total assets | ₩711.72b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A950210's short term assets (₩250.4B) exceed its short term liabilities (₩145.9B).
Long Term Liabilities: A950210's short term assets (₩250.4B) exceed its long term liabilities (₩50.4B).
Debt to Equity History and Analysis
Debt Level: A950210 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A950210's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A950210 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A950210 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 23.2% each year.